Genetic microheterogeneity and phenotypic variation of Helicobacter pylori arginase in clinical isolates
- PMID: 17408487
- PMCID: PMC1853099
- DOI: 10.1186/1471-2180-7-26
Genetic microheterogeneity and phenotypic variation of Helicobacter pylori arginase in clinical isolates
Abstract
Background: Clinical isolates of the gastric pathogen Helicobacter pylori display a high level of genetic macro- and microheterogeneity, featuring a panmictic, rather than clonal structure. The ability of H. pylori to survive the stomach acid is due, in part, to the arginase-urease enzyme system. Arginase (RocF) hydrolyzes L-arginine to L-ornithine and urea, and urease hydrolyzes urea to carbon dioxide and ammonium, which can neutralize acid.
Results: The degree of variation in arginase was explored at the DNA sequence, enzyme activity and protein expression levels. To this end, arginase activity was measured from 73 minimally-passaged clinical isolates and six laboratory-adapted strains of H. pylori. The rocF gene from 21 of the strains was cloned into genetically stable E. coli and the enzyme activities measured. Arginase activity was found to substantially vary (>100-fold) in both different H. pylori strains and in the E. coli model. Western blot analysis revealed a positive correlation between activity and amount of protein expressed in most H. pylori strains. Several H. pylori strains featured altered arginase activity upon in vitro passage. Pairwise alignments of the 21 rocF genes plus strain J99 revealed extensive microheterogeneity in the promoter region and 3' end of the rocF coding region. Amino acid S232, which was I232 in the arginase-negative clinical strain A2, was critical for arginase activity.
Conclusion: These studies demonstrated that H. pylori arginase exhibits extensive genotypic and phenotypic variation which may be used to understand mechanisms of microheterogeneity in H. pylori.
Figures






Similar articles
-
Helicobacter pylori rocF is required for arginase activity and acid protection in vitro but is not essential for colonization of mice or for urease activity.J Bacteriol. 1999 Dec;181(23):7314-22. doi: 10.1128/JB.181.23.7314-7322.1999. J Bacteriol. 1999. PMID: 10572136 Free PMC article.
-
Purification and characterization of Helicobacter pylori arginase, RocF: unique features among the arginase superfamily.Eur J Biochem. 2004 May;271(10):1952-62. doi: 10.1111/j.1432-1033.2004.04105.x. Eur J Biochem. 2004. PMID: 15128304
-
Helicobacter pylori arginase mutant colonizes arginase II knockout mice.World J Gastroenterol. 2011 Jul 28;17(28):3300-9. doi: 10.3748/wjg.v17.i28.3300. World J Gastroenterol. 2011. PMID: 21876618 Free PMC article.
-
[Development of genetic and molecular approaches for the diagnosis and the study of the pathogenic power of Helicobacter pylori, agent of inflammatory gastric diseases].Ann Gastroenterol Hepatol (Paris). 1992 Mar-Apr;28(2):93-7. Ann Gastroenterol Hepatol (Paris). 1992. PMID: 1622109 Review. French.
-
Diversity, properties and functions of bacterial arginases.FEMS Microbiol Rev. 2021 Nov 23;45(6):fuab034. doi: 10.1093/femsre/fuab034. FEMS Microbiol Rev. 2021. PMID: 34160574 Review.
Cited by
-
In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors.Mol Divers. 2022 Dec;26(6):3365-3378. doi: 10.1007/s11030-021-10371-8. Epub 2022 Jan 8. Mol Divers. 2022. PMID: 34997872
-
Arginase of Helicobacter Gastric Pathogens Uses a Unique Set of Non-catalytic Residues for Catalysis.Biophys J. 2017 Mar 28;112(6):1120-1134. doi: 10.1016/j.bpj.2017.02.009. Biophys J. 2017. PMID: 28355540 Free PMC article.
-
Expression of three essential antioxidants of Helicobacter pylori in clinical isolates.J Zhejiang Univ Sci B. 2014 May;15(5):500-6. doi: 10.1631/jzus.B1300171. J Zhejiang Univ Sci B. 2014. PMID: 24793768 Free PMC article.
-
Transcriptional profiling of gastric epithelial cells infected with wild type or arginase-deficient Helicobacter pylori.BMC Microbiol. 2012 Aug 13;12:175. doi: 10.1186/1471-2180-12-175. BMC Microbiol. 2012. PMID: 22889111 Free PMC article.
-
Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura.Int J Hematol. 2009 Mar;89(2):142-149. doi: 10.1007/s12185-008-0247-4. Epub 2009 Jan 30. Int J Hematol. 2009. PMID: 19184277
References
-
- Blaser MJ. Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology. 1987;93:371–383. - PubMed
-
- Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. Journal of Infectious Diseases. 1990;161:626–633. - PubMed
-
- Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Medical Journal of Australia. 1985;142:439–444. - PubMed
-
- Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.[see comment] New England Journal of Medicine. 1991;325:1132–1136. - PubMed
-
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases